YieldMax AI & Tech Portfolio Option Income ETF vs Regeneron Pharmaceuticals Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.99 (market cap $135.69M), while Regeneron Pharmaceuticals Inc trades at $740.01 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 561.1× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while YieldMax AI & Tech Portfolio Option Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 60 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| GPTY | REGN | |
|---|---|---|
Market Cap | $135.69M | $76.14B |
Volume | 97,442 | 500,239 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $852.03 |
52-Week Low | $34.73 | $557.73 |
Typical Hold Time | 60 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →